Placebo | EMLA | |||
---|---|---|---|---|
Variable | Pre-procedure phase | Procedure phase | Pre-procedure phase | Procedure phase |
Heart rate(bpm) | 157 (126–170) | 159 (127–181) | 158 (134–175) | 163 (144–179) |
Oxygen saturation % | 97 (92–99) | 96 (91–99) | 98 (95–100) | 96 (93–98) |
Systolic BP mm Hg | 61 (45–85) | 69 (56–87) | 63 (45–88) | 67 (51–86) |
Diastolic BP mm Hg | 36 (23–51) | 41 (29–50) | 39 (27–54) | 39 (25–62) |
NFCS1-150 | 1 (0–6) | 5 (0–8) | 0 (0–4) | 6 (0–7) |
DFC^ (s) | NA | 13 (0–411) | NA | 6 (0–260) |
TDC1-160 (s) | NA | 43 (0–411) | NA | 6 (0–361) |
Methaemoglobin % 1 h | NA | 1.2 (0.7–2.0) | NA | 1.6 (0.7–4.4) |
Methaemoglobin % 8 h | NA | 1.5 (0.8–2.1) | NA | 1.7 (1.2–6.7) |